<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B4FD9AE2-8245-4FE9-BAAD-7E6DFDD952DD"><gtr:id>B4FD9AE2-8245-4FE9-BAAD-7E6DFDD952DD</gtr:id><gtr:name>Great Western Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A88086FE-C28F-4863-8B2B-1A97734A6C79"><gtr:id>A88086FE-C28F-4863-8B2B-1A97734A6C79</gtr:id><gtr:name>University of Strasbourg</gtr:name><gtr:address><gtr:line1>Universite Louis Pasteur</gtr:line1><gtr:line2>4 rue Blaise Pascal</gtr:line2><gtr:line4>Strasbourg</gtr:line4><gtr:line5>Cedex</gtr:line5><gtr:postCode>67070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0DE10BF6-639D-43F2-8A56-04B727EC99C5"><gtr:id>0DE10BF6-639D-43F2-8A56-04B727EC99C5</gtr:id><gtr:name>University of Stavanger</gtr:name><gtr:address><gtr:line1>University of Stavanger</gtr:line1><gtr:postCode>N-4036</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BC62F3B4-8F22-4AD0-8F9F-57966529DE73"><gtr:id>BC62F3B4-8F22-4AD0-8F9F-57966529DE73</gtr:id><gtr:name>The Dudley Group NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF390CF0-ECD3-47D8-B9A8-7602AF319BEE"><gtr:id>EF390CF0-ECD3-47D8-B9A8-7602AF319BEE</gtr:id><gtr:name>Northumbria University</gtr:name><gtr:address><gtr:line1>Ellison Place</gtr:line1><gtr:line4>Newcastle upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 8ST</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DAA623C1-3BA1-4561-8942-0EFE5069C974"><gtr:id>DAA623C1-3BA1-4561-8942-0EFE5069C974</gtr:id><gtr:name>Nascient ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/13F70662-CB09-4DCE-94F5-CEDE5C696FAE"><gtr:id>13F70662-CB09-4DCE-94F5-CEDE5C696FAE</gtr:id><gtr:name>The European League Against Rheumatism (EULAR)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1FADA516-503F-4D04-96FD-28248BF7B77E"><gtr:id>1FADA516-503F-4D04-96FD-28248BF7B77E</gtr:id><gtr:name>The Binding Site</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3CF8F93E-AA21-4068-BA17-315E439CBF84"><gtr:id>3CF8F93E-AA21-4068-BA17-315E439CBF84</gtr:id><gtr:name>Oklahoma Medical Research Foundation (OMRF)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AFCF678A-5FC2-4D86-B376-12C1457C0F14"><gtr:id>AFCF678A-5FC2-4D86-B376-12C1457C0F14</gtr:id><gtr:name>Columbia University Medical Center</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B4FD9AE2-8245-4FE9-BAAD-7E6DFDD952DD"><gtr:id>B4FD9AE2-8245-4FE9-BAAD-7E6DFDD952DD</gtr:id><gtr:name>Great Western Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A88086FE-C28F-4863-8B2B-1A97734A6C79"><gtr:id>A88086FE-C28F-4863-8B2B-1A97734A6C79</gtr:id><gtr:name>University of Strasbourg</gtr:name><gtr:address><gtr:line1>Universite Louis Pasteur</gtr:line1><gtr:line2>4 rue Blaise Pascal</gtr:line2><gtr:line4>Strasbourg</gtr:line4><gtr:line5>Cedex</gtr:line5><gtr:postCode>67070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0DE10BF6-639D-43F2-8A56-04B727EC99C5"><gtr:id>0DE10BF6-639D-43F2-8A56-04B727EC99C5</gtr:id><gtr:name>University of Stavanger</gtr:name><gtr:address><gtr:line1>University of Stavanger</gtr:line1><gtr:postCode>N-4036</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BC62F3B4-8F22-4AD0-8F9F-57966529DE73"><gtr:id>BC62F3B4-8F22-4AD0-8F9F-57966529DE73</gtr:id><gtr:name>The Dudley Group NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF390CF0-ECD3-47D8-B9A8-7602AF319BEE"><gtr:id>EF390CF0-ECD3-47D8-B9A8-7602AF319BEE</gtr:id><gtr:name>Northumbria University</gtr:name><gtr:address><gtr:line1>Ellison Place</gtr:line1><gtr:line4>Newcastle upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 8ST</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DAA623C1-3BA1-4561-8942-0EFE5069C974"><gtr:id>DAA623C1-3BA1-4561-8942-0EFE5069C974</gtr:id><gtr:name>Nascient ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/13F70662-CB09-4DCE-94F5-CEDE5C696FAE"><gtr:id>13F70662-CB09-4DCE-94F5-CEDE5C696FAE</gtr:id><gtr:name>The European League Against Rheumatism (EULAR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1FADA516-503F-4D04-96FD-28248BF7B77E"><gtr:id>1FADA516-503F-4D04-96FD-28248BF7B77E</gtr:id><gtr:name>The Binding Site</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3CF8F93E-AA21-4068-BA17-315E439CBF84"><gtr:id>3CF8F93E-AA21-4068-BA17-315E439CBF84</gtr:id><gtr:name>Oklahoma Medical Research Foundation (OMRF)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AFCF678A-5FC2-4D86-B376-12C1457C0F14"><gtr:id>AFCF678A-5FC2-4D86-B376-12C1457C0F14</gtr:id><gtr:name>Columbia University Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DFF758C5-064B-4650-8CA2-94D1953CB6A7"><gtr:id>DFF758C5-064B-4650-8CA2-94D1953CB6A7</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Bowman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A21F0EF9-D1BB-4A9D-A490-4C7D204E54F9"><gtr:id>A21F0EF9-D1BB-4A9D-A490-4C7D204E54F9</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Griffiths</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B8337C44-7C9D-4E5C-9D4B-EC284605F8E2"><gtr:id>B8337C44-7C9D-4E5C-9D4B-EC284605F8E2</gtr:id><gtr:firstName>Wan-Fai</gtr:firstName><gtr:surname>Ng</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1A5E536E-908D-4EF4-B9F1-2FB3BFDA0A6A"><gtr:id>1A5E536E-908D-4EF4-B9F1-2FB3BFDA0A6A</gtr:id><gtr:firstName>Bridget</gtr:firstName><gtr:surname>Griffiths</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800629"><gtr:id>662C5453-2D8A-47EC-B9A9-5ED8D1C87A60</gtr:id><gtr:title>United Kingdom Primary Sjogren's Syndrome Registry (UKPSSR)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800629</gtr:grantReference><gtr:abstractText>Primary Sjogren s syndrome (PSS) is a chronic condition that affect up to 3% of adults in the United Kingdom (UK). Although the commonest symptoms of PSS are dry eye, dry mouth, joint pain and profound fatigue, almost any part of the body can be affected. Moreover, PSS is associated with 40 times higher risk of developing lymphoma (a form of cancer). Patients with PSS also have poor quality of life and a significant proportion of PSS patients are unable to work because of their disease. Unfortunately, we know very little about what causes PSS and we have not found any effective treatment. However, several recent developments in PSS research have created a platform for finding new treatment for PSS and improving our understanding of the underlying disease processes of PSS. Firstly, the UK Sjogren?s Interest Group (UKSIG) have developed standardised methods to assess patients with PSS, so that we can test how good a specific treatment is and make comparison with other treatments. Secondly, a number of promising therapies for PSS have been developed in the last few years. Thirdly, emerging new research technologies offer new approaches in PSS research. The aim of this project is to capitalise on these recent developments by creating a database of 500 patients with PSS over a period of 3 years so that new treatments for PSS can be tested more quickly and efficiently and clinical studies can be carried out more effectively. We need so many patients because not all patients are suitable for all studies. We will assess the patients using the standardised methods mentioned earlier and blood samples from these patients will be stored for future research. Patients will be recruited from 24 hospitals across the UK and the assessment will be carried out at the local clinics. This is a UKSIG project, co-ordinated by doctors from Newcastle University, the Freeman Hospital and University Hospital of Birmingham. Many doctors involved in this project have participated in previous multi-centre studies organised by the UKSIG. The proposed database will provide a unique and valuable resource for clinical and academic studies as well as for identifying suitable patients for clinical trials. The database will make it quicker and easier to organise these studies. Furthermore, this project will encourage collaborative research between academia, National Health Service and industry, and will promote the use of standardised assessments in the management of patients with PSS.</gtr:abstractText><gtr:technicalSummary>Primary Sjogren s syndrome (PSS) is a chronic multi-system disease that affect up to 3% of adults in the United Kingdom. Although sicca symptoms, joint pain and fatigue are the commonest symptoms of PSS, almost any organs can be affected and there is a 40-fold increased risk of developing lymphoma. However, little is known regarding the pathogenesis and effective treatment has not been identified. The recent development of standardised outcome measures by the UK Sjogren?s Interest Group (UKSIG) and others have generated criteria by which the effectiveness of specific therapy can be judged and compared. Furthermore, emerging biological treatments, notably anti-B cell therapies, have shown promising results in improving fatigue, sicca symptoms and systemic features of PSS. These recent developments have provided the framework for testing new therapies in PSS and performing other clinical studies. The aim of this project is to create a cohort of 500 well-characterised PSS patients in order to facilitate such proof-of-concept clinical trials, observational and longitudinal studies in PSS. 500 patients is required because not all patients are suitable for all studies. PSS patients will be identified from existing databases of the 24 collaborating hospitals. After obtaining written consent, patients will be assessed for severity of the key symptoms, disease activity and organ damage and health-related quality of life. These assessments include patient-completed questionnaires, physical examination, bedside clinical tests, laboratory tests of peripheral blood and urine. All assessments will be completed in a single outpatient visit, and all laboratory tests are readily available in all recruiting hospitals. In addition, we will store serum, DNA and RNA samples from patients for future studies. We will develop a database software specifically for this registry. All clinical data and biological materials will be stored in anonymised-linked format. The proposed registry wilprovide a unique and valuable resource for clinical and academic studies as well as for identifying suitable patients for clinical trials and other clinical studies. The creation of a well-characterised cohort of PSS patients will significantly reduce the cost of screening patients for these studies and will increase the appeal for sponsorship from industry for these proof-of-concept studies. This project will also foster collaborative research between academia, National Health Service (NHS) and industry, and promote the use of standardised assessment tools in managing patients with PSS. Finally, since this cohort will be the largest of its kind, it will also generate invaluable epidemiological data.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>542469</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The European League Against Rheumatism (EULAR)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Validation of European primary Sj&amp;ouml;gren's syndrome disease activity index and patient reported index study</gtr:description><gtr:id>BC47A952-A210-4515-BBAB-215831B4B040</gtr:id><gtr:impact>Recruitment has been completed, data analysis ongoing</gtr:impact><gtr:outcomeId>NgQhNNCQ34Q-1</gtr:outcomeId><gtr:partnerContribution>Widening our collaborative network with our European collaegues, and utilisation of the UKPSSR cohort</gtr:partnerContribution><gtr:piContribution>Utilisation of the cohort. One of the Co-Is is a member of the steering committee of this project.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oklahoma Medical Research Foundation (OMRF)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Autoimmune Research Group</gtr:department><gtr:description>Sjogren's Genetic Network</gtr:description><gtr:id>B800A87E-1C33-48D3-B18A-E4BDDF65308B</gtr:id><gtr:impact>Publication of the first phase of the GWAS study in Nature Genetics in 2013. We were the single largest provider of Sjogren's DNA samples and data.</gtr:impact><gtr:outcomeId>gLBhfTvAoKr-1</gtr:outcomeId><gtr:partnerContribution>Utilisation of biological samples of the UKPSSR, and will be co-author on any data published using the samples</gtr:partnerContribution><gtr:piContribution>Provide biological samples and associated clinical data for the genome-wide association study and other subsequent validation studies.
In addition, our collaboration has play a key role for the collaborator group's success in securing a NIH centre grant of over US$1.6 million</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Erasmus University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Research Collaboration - Interferon signature in PSS</gtr:description><gtr:id>17B197CC-FEE3-468D-84D0-83382FFB0C93</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>545a24d04fae48.67749681-1</gtr:outcomeId><gtr:partnerContribution>Conducting experiments</gtr:partnerContribution><gtr:piContribution>Providing samples for research and contribute to research design, data analysis and interpretation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Computing Science</gtr:department><gtr:description>Identifying the biological signature of fatigue</gtr:description><gtr:id>B7124AF0-9BF4-4614-B22E-A465AF61D2BA</gtr:id><gtr:impact>Project been awarded recently, to be started in early 2012</gtr:impact><gtr:outcomeId>cWZ8qV4FJBT-3</gtr:outcomeId><gtr:partnerContribution>Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment</gtr:partnerContribution><gtr:piContribution>PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Dental Sciences Liverpool</gtr:department><gtr:description>Anti-M3R antibodies, autonomic dysfunction and primary Sjogren's syndrome</gtr:description><gtr:id>F10D4F08-E995-4B07-8D75-94E407E79FA6</gtr:id><gtr:impact>Recruitment has now been completed. The data are being analysed for publication</gtr:impact><gtr:outcomeId>A68253AA672-1</gtr:outcomeId><gtr:partnerContribution>Promote cohort utilisation and foster collaboration between researchers with an interest in primary Sjogren's syndrome</gtr:partnerContribution><gtr:piContribution>Established the collaboration, contribute the grant application which was awarded by the arc. Organise samples from the cohort to be sent to collaborations for the study. Recruitment from the cohort to take part in the study.
Both PI and Co-I Bowman are co-investigators of this project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Dudley Group NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CV risk in primary Sjogren's syndrome</gtr:description><gtr:id>A742903F-253E-484E-8520-A0B53B45F3B3</gtr:id><gtr:impact>We have obtained a favourable opinion from the REC, and the study has been adopted into the NIHR portfolio. Recruitment has now been completed for PSS patients, recruitment for healthy controls ongoing. Preliminary analysis being written up for publication.</gtr:impact><gtr:outcomeId>CE2E34B4908-1</gtr:outcomeId><gtr:partnerContribution>Promote the utilisation of the cohort and foster collaborative link between researchers with an interest in primary SJogren's syndrome research</gtr:partnerContribution><gtr:piContribution>Data collection, recruitment, and prepare grant application which was awarded by the British Sjogren's syndrome association. This project is led by the PI of the UKPSSR.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The European League Against Rheumatism (EULAR)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>EULAR Sjogren's Syndrome Management Guideline Steering group</gtr:description><gtr:id>A3799911-B239-4CF7-B220-0435EB353A5E</gtr:id><gtr:impact>Only recently started</gtr:impact><gtr:outcomeId>545a1ad200a0c0.95444698-1</gtr:outcomeId><gtr:partnerContribution>Provide expertise in Sjogren's syndrome and to coordinate opinions from participating members to construct a consensus guideline</gtr:partnerContribution><gtr:piContribution>Provide expertise in Sjogren's syndrome</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Barts and The London School of Medicine and Dentistry</gtr:department><gtr:description>RCT of rituximab in primary Sjogren's syndrome</gtr:description><gtr:id>1534BDBE-3E11-496B-8AC8-6EDAD21E5E9A</gtr:id><gtr:impact>Recruitment has started in August 2011 with a recruitment period of 2 years. This study aims to study 110 patient</gtr:impact><gtr:outcomeId>6DD7012362A-2</gtr:outcomeId><gtr:partnerContribution>Utilisation of the cohort, promote collaboration between researchers with an interest in primary Sjogren's syndromeUtilisation of the cohort data for patient selection</gtr:partnerContribution><gtr:piContribution>Co-I of this project is the PI of this clinical trial. The clinical data of the cohort is being used to select participation centres and potential patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:description>Epigenetic regulation of gene expression in primary Sj&amp;ouml;gren's syndrome</gtr:description><gtr:id>9E91361D-FBD3-4B7D-940F-B4562A73F7E1</gtr:id><gtr:impact>This is a PhD studentship in year 1 of the project.</gtr:impact><gtr:outcomeId>byYAK7MZ1yL-1</gtr:outcomeId><gtr:partnerContribution>Utilisation of the biobanked samples and clinical data of the cohort.
Also develop new area of research</gtr:partnerContribution><gtr:piContribution>PI of the UKPSSR is also PI of this project, who contribute to the design and management of this project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oklahoma Medical Research Foundation (OMRF)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Autoimmune Research Group</gtr:department><gtr:description>Oklahoma Sj&amp;ouml;gren's Syndrome Centre of Research Translation</gtr:description><gtr:id>E482D563-ABCD-4A12-A9D6-63A81C03F342</gtr:id><gtr:impact>Research project still ongoing</gtr:impact><gtr:outcomeId>AxZDvuvZ96D-1</gtr:outcomeId><gtr:partnerContribution>This collaboration strengthens our partnership with Oklahoma Medical Research Foundation which we have established in the Sjogren's genetic Network project.</gtr:partnerContribution><gtr:piContribution>The UKPSSR is a key collaboration partner for this 5-year centre grant (US$1.6 million) funded by the National Institution of Health, US. The collaboration agreement involves us continue our contribution of biobanked samples and clinical data for appropriate research projects into Sjogren's syndrome</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nascient ltd</gtr:collaboratingOrganisation><gtr:country>Unknown</gtr:country><gtr:description>Research collaboration - new target validation</gtr:description><gtr:id>ACE7E5D0-46B3-424E-BD7A-C83EC0E8C0B4</gtr:id><gtr:impact>Our pilot work has confirm the presence of the target in the biobanked samples. We are now in discussion of validating the findings using a bigger sample size</gtr:impact><gtr:outcomeId>58b1b9a0613736.25783817-1</gtr:outcomeId><gtr:partnerContribution>Financial and the candidate target to be tested</gtr:partnerContribution><gtr:piContribution>Perform target validation on biobanked samples</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute for Ageing and Health</gtr:department><gtr:description>Identifying the biological signature of fatigue</gtr:description><gtr:id>B14B8797-69AF-4676-8E35-6A50B72A6A45</gtr:id><gtr:impact>Project been awarded recently, to be started in early 2012</gtr:impact><gtr:outcomeId>cWZ8qV4FJBT-5</gtr:outcomeId><gtr:partnerContribution>Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment</gtr:partnerContribution><gtr:piContribution>PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Northumbria University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Development of a user-informed invention to improve the function of primary Sjogren's syndrome patients</gtr:description><gtr:id>4A895865-7A86-4CAA-9E18-C89D06E3B735</gtr:id><gtr:impact>Partnership has only just started</gtr:impact><gtr:outcomeId>ZGYpR8DosEz-1</gtr:outcomeId><gtr:partnerContribution>Assistance in data analysis and non-pharmacologica aspect of intervention development</gtr:partnerContribution><gtr:piContribution>provide intellectual input on study design, using UKPSSR data for inviting partient to participating in this study</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Binding Site</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Research collaboration</gtr:description><gtr:id>39A9C45D-FED9-4107-983A-62A66DA9A77A</gtr:id><gtr:impact>Analysis complete, preparing manuscript for publication</gtr:impact><gtr:outcomeId>CbuhWf29LWc-1</gtr:outcomeId><gtr:partnerContribution>Analyse the samples for the agreed analytes of interest and provide support in data analysis. All raw data generated will be returned to the UKPSSR for storage and future use</gtr:partnerContribution><gtr:piContribution>Provide biobanked serum sample and anonymised clinical data for the research project</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Leeds Clinical Trials Unit</gtr:department><gtr:description>RCT of rituximab in primary Sjogren's syndrome</gtr:description><gtr:id>F5395D7B-BA2C-43F4-ABFE-EB6E1EE0B211</gtr:id><gtr:impact>Recruitment has started in August 2011 with a recruitment period of 2 years. This study aims to study 110 patient</gtr:impact><gtr:outcomeId>6DD7012362A-1</gtr:outcomeId><gtr:partnerContribution>Utilisation of the cohort, promote collaboration between researchers with an interest in primary Sjogren's syndromeUtilisation of the cohort data for patient selection</gtr:partnerContribution><gtr:piContribution>Co-I of this project is the PI of this clinical trial. The clinical data of the cohort is being used to select participation centres and potential patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Columbia University Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Division of Infectious Diseases</gtr:department><gtr:description>Dissecting the possible infective links in primary Sj&amp;ouml;gren's syndrome</gtr:description><gtr:id>9B1928BE-83DD-4291-A819-BEB5294A0DFB</gtr:id><gtr:impact>We are currently collecting additional samples according to the collaborators recommendation</gtr:impact><gtr:outcomeId>kgbUAvCiMzX-1</gtr:outcomeId><gtr:partnerContribution>Develop novel area of research, utilisation of biobanked samples</gtr:partnerContribution><gtr:piContribution>PI of the UKPSSR initiated the collaboration, utilisation of the biobanked smaples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Uppsala University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Rheumatology</gtr:department><gtr:description>Candidate gene association study in primary Sjogren's syndrome</gtr:description><gtr:id>11122AD3-AFCE-4E1C-899E-AB741EC6FEA9</gtr:id><gtr:impact>All the required samples have been sent, data are being analyzed.</gtr:impact><gtr:outcomeId>jWTdmv5FrCY-1</gtr:outcomeId><gtr:partnerContribution>Utilization of the UKPSSR biobanked DNA samples and accompanied clinical data</gtr:partnerContribution><gtr:piContribution>We contribute the biobanked DNA samples and clinical data for this study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Uppsala University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Research Collaboration - identify miRNA biomarkers in PSS-associated lymphoma</gtr:description><gtr:id>5BB2365A-7F82-4E59-A9D9-3DC27FA046B4</gtr:id><gtr:impact>Potential biomarker</gtr:impact><gtr:outcomeId>545a241f577821.17375961-1</gtr:outcomeId><gtr:partnerContribution>Providing samples</gtr:partnerContribution><gtr:piContribution>Performing research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Rheumatology University Hospitals Birmingham</gtr:department><gtr:description>Identifying the biological signature of fatigue</gtr:description><gtr:id>40EF5EB4-1FFB-4EBF-8FC7-2AC713097FBB</gtr:id><gtr:impact>Project been awarded recently, to be started in early 2012</gtr:impact><gtr:outcomeId>cWZ8qV4FJBT-1</gtr:outcomeId><gtr:partnerContribution>Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment</gtr:partnerContribution><gtr:piContribution>PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute for Ageing and Health</gtr:department><gtr:description>The prevalence and predictor of autonomic dysfunction in primary Sj&amp;ouml;gren's syndrome</gtr:description><gtr:id>7FAEDB70-9BA9-44F1-B378-D615ABE8DAB6</gtr:id><gtr:impact>Manuscript submitted to a peer-reviewed scientific journal</gtr:impact><gtr:outcomeId>pRKyYi1xPsF-1</gtr:outcomeId><gtr:partnerContribution>Utilisation of the cohort data</gtr:partnerContribution><gtr:piContribution>The clinical data of the cohort were utilized for this study, PI of the UKPSSR contribute to the design and data analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute for Cell and Molecular Biosciences</gtr:department><gtr:description>Identifying the biological signature of fatigue</gtr:description><gtr:id>B732A392-50F5-43BF-81B4-B3E3B2042B44</gtr:id><gtr:impact>Project been awarded recently, to be started in early 2012</gtr:impact><gtr:outcomeId>cWZ8qV4FJBT-4</gtr:outcomeId><gtr:partnerContribution>Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment</gtr:partnerContribution><gtr:piContribution>PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Stavanger</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Immunology</gtr:department><gtr:description>Research Grant application</gtr:description><gtr:id>9AD962A4-224F-4D45-BD50-769BB9F30075</gtr:id><gtr:impact>Awaiting outcome of the application</gtr:impact><gtr:outcomeId>TnEDF5WVVqm-1</gtr:outcomeId><gtr:partnerContribution>Conduct the experiments described in the grant application</gtr:partnerContribution><gtr:piContribution>Provide biobanked DNA and serum samples for the research project, if the application to the Norwegian Research Council is successful</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Cellular and Molecular Physiology (CCMP)</gtr:department><gtr:description>Metabolomic signatures in Primary Sjogren's syndrome</gtr:description><gtr:id>75216FA3-693F-47ED-871A-D9D54BC8A314</gtr:id><gtr:impact>We are currently analyzing the pilot data, and in preparation for a grant application to extend the work.</gtr:impact><gtr:outcomeId>K9BBo4WKqto-1</gtr:outcomeId><gtr:partnerContribution>Establish new collaboration and novel area of research. Utilisation of the biobanked serum samples and clinical data</gtr:partnerContribution><gtr:piContribution>PI contribute to the design and conceptualisation of the project. We contribute also the biobanked serum samples and clinical data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Great Western Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Rheumatology Department Great Western Hospitals</gtr:department><gtr:description>Identifying the biological signature of fatigue</gtr:description><gtr:id>8B2A63A5-B5B9-495A-B367-48DA53345B2B</gtr:id><gtr:impact>Project been awarded recently, to be started in early 2012</gtr:impact><gtr:outcomeId>cWZ8qV4FJBT-2</gtr:outcomeId><gtr:partnerContribution>Patient recruitmentPatient recruitmentExpertise in bioinformaticData analysisPatient recruitment</gtr:partnerContribution><gtr:piContribution>PI of the UKPSSR conceptualizes this project, the biobanked data and samples of the UKPSSR will be used for this project</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Dental Sciences</gtr:department><gtr:description>Clinical utility of ultrasound in the diagnosis and management of primary Sjogren's syndrome</gtr:description><gtr:id>C3B9C6E6-5BB6-4718-B1E5-8A6305A4462F</gtr:id><gtr:impact>The ACF has started his post in November 2011, in the next 12-month, we will be generating high quality pilot data for making a Clinical Training Fellowship application for a PhD.</gtr:impact><gtr:outcomeId>chpsVNsB6Ke-1</gtr:outcomeId><gtr:partnerContribution>Establish new collaboration and new area of research</gtr:partnerContribution><gtr:piContribution>The PI is the academic supervisor of the newly appointed NIHR Academic clinical fellow (ACF) in dental radiology. This is the first dental radiology ACF ever been appointed in the UK</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Strasbourg</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Research collaboration - validation</gtr:description><gtr:id>1765D951-FFF0-49D7-B74C-488332463FA3</gtr:id><gtr:impact>Oral presentation at American College of Rheumatology Annual Conference and Won the best abstract prize in Sjogren's syndrome</gtr:impact><gtr:outcomeId>58b1be693dcfb9.95604712-1</gtr:outcomeId><gtr:partnerContribution>Provide anonymised data for validation</gtr:partnerContribution><gtr:piContribution>Generate original data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Stavanger</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>Research collaboration - validation</gtr:description><gtr:id>9307F18F-A401-4535-819C-D6B5EDDEFEB3</gtr:id><gtr:impact>Oral presentation at American College of Rheumatology Annual Conference and Won the best abstract prize in Sjogren's syndrome</gtr:impact><gtr:outcomeId>58b1be693dcfb9.95604712-2</gtr:outcomeId><gtr:partnerContribution>Provide anonymised data for validation</gtr:partnerContribution><gtr:piContribution>Generate original data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Paper presentations (EULAR 2011)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5AAABA40-B3B7-4B02-8D8A-4B3EE0166D71</gtr:id><gtr:impact>2 poster presentations at the Annual Meeting of the European League Against Rheumatism, London, 25-28 May 2011.

Improve the profile of the UKPSSR and Sjogren's syndrome research</gtr:impact><gtr:outcomeId>fdiYA6P5Xzo</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk (Industry)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5D3BAB19-D0A2-4C49-8376-544F63319C70</gtr:id><gtr:impact>I was invited to give a lecture on Sjogren's syndrome to 30-40 researchers from a pharmaceutical company in Slough, followed by a discussion with leaders of relevant research groups on potential Sjogren's related research project.

Several potential research projects were discussed but did not progressed further at present largely due to perceived lack of market potential.</gtr:impact><gtr:outcomeId>AJs8KPumaYK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk (Brest 2009)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B52C29D6-4C36-4F28-BAD2-986A201B0620</gtr:id><gtr:impact>Presentation at the 10th International Symposium of Sjogren's syndrome (Brest, 1-3 Oct, 2009), on the establishment of the UK primary Sjogren's syndrome registry

Established several international research collaborations, thus promoting utility of the patient cohort and biobank.</gtr:impact><gtr:outcomeId>kPdwChKVzpb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Proximity to Discovery themed week</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>236F3B3E-4502-4108-B0CC-316C1AD62B07</gtr:id><gtr:impact>This is a week of engagement activity targeting senior members of pharmaceutical/biotechnology industry to promote collaboration.
representatives from 5 pharmaceutical companies and a biotech company attended the meeting.
All companies showed great interest in our research into Sjogren's and fatigue.</gtr:impact><gtr:outcomeId>56d1c614ea9742.49511718</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Paper presentation (Berlin 2012)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6FEF0C4D-2C40-411B-80A6-24C107C9E81B</gtr:id><gtr:impact>3 poster presentations at the European League Against Rheumatism Annual Meeting, Berlin, 6-9 June, 2012)

Improve the profile of UKPSSR and new collaborative projects conceptualised.</gtr:impact><gtr:outcomeId>XgSFsq8pyxH</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>paper presentation (BSR 2012)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CDFD9B1D-D135-4FDC-82EF-C713483E6A33</gtr:id><gtr:impact>Oral and poster presentations of work from the UKPSSR at the British Society for Rheumatology Annual Conference, Glasgow, 1-3 May 2012

Improve profile of the UKPSSR and data dissemination to participants of the UKPSSR</gtr:impact><gtr:outcomeId>JbNPLXzgeBo</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Paper presentation - ISSS (Athens)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E9BD04BD-FC8C-49EB-8BF2-0FF98783974F</gtr:id><gtr:impact>Poster presentations at the 11th International Symposium on Sjogren's Syndrome, Athens, 28 Sept-1 Oct, 2012

Improve the profile of Sjogren's syndrome research and the UKPSSR, established new research collaboration.</gtr:impact><gtr:outcomeId>cgi1ZvK98YT</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk (BSR annual conference, 2014)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AFF61DDE-C6BF-4F5D-877E-126D0CCD73F6</gtr:id><gtr:impact>Improve the profile of fatigue research

New collaborative research being established</gtr:impact><gtr:outcomeId>545a7560844a47.64337902</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk - ME Research UK North East</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A918613B-7C3C-48D6-A8D3-21622F1F1327</gtr:id><gtr:impact>Invited speaker at the ME Research UK North East Annual meeting.

Engagement with patients with shared features of Sjogren's syndrome.</gtr:impact><gtr:outcomeId>sZea2Ed6mRZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk (London 2012)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CD20A06F-45CD-4BB3-BFE0-20552B712D1C</gtr:id><gtr:impact>Presentation at the Franco-British Bilateral Symposium on strengthening translational research &amp;amp; clinical trials across the 2 countries. I was invited to speak on how to establish a large multi-centre patient cohort and biobank, especially on how to maintain high standards of the data and samples collected.

Raised the profile of the UKPSSR and Sjogren's research.</gtr:impact><gtr:outcomeId>Gew4J1ejGVh</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Paper presentation - BSR (2011)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D359E8B5-AF49-436B-9AF0-CCAE90E8EF65</gtr:id><gtr:impact>Oral and poster presentations at the British Society for Rheumatology Annual Meeting, Brighton, 12-14 April, 2011

Improve he profile of the UKPSSR</gtr:impact><gtr:outcomeId>Y5cjXWY7eiE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual Conference of a patients' association</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E185E7FC-29FC-4DE5-A0B8-0FFD6E76A491</gtr:id><gtr:impact>Give a oral presentation regarding this cohort at the annual conference of the British Sjogren's syndrome Association - its aims and what it means to clinicians and patients. Afterwards, the PI also contribute a newsletter article.

We received many enquiries on how to take part in the project.</gtr:impact><gtr:outcomeId>E28D40E2C79</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual Scandinavian Sjogren's Research Meeting (Krusenberg, Sweden)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>773B635E-EE0C-42A5-9541-4AF50300FB9A</gtr:id><gtr:impact>Presentation at the annual meeting of the Scandinavian Sjogren's Syndrome Research Network. Krusenberg, Sweden. 1-2 Sept 2011. A 2-day workshop on Sjogren's research in Scandinavia (with approximately 50 participants with research interest in Sjogren's syndrome)

New collaborative research projects identified. Strengthening the collaboration that we have previously established with a research group in Sweden.</gtr:impact><gtr:outcomeId>guEkDyUAphi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk (CFS/ME collaborative, Bristol, 2014)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FC80B952-2367-4C81-82FF-E59941969B43</gtr:id><gtr:impact>Raising interest in the area of my research

Dissemination of research idea and data</gtr:impact><gtr:outcomeId>545a7451d1ac63.35156540</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk (Newcastle 2012)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2F97E99C-925D-4FAD-A8D4-1EFC77EFCF72</gtr:id><gtr:impact>Presentation at the Annual Meeting of the British Sjogren's syndrome Association (Newcastle, 15 Sept 2012) on the immune system and theimmunological basis in Sjogren's syndrome

Engagement with patients with Sjogren's syndrome and their relatives/carers</gtr:impact><gtr:outcomeId>mUDDqJYwULF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EULAR annual meeting (Rome, 2015)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8F460B9F-E48B-4BF7-B2E7-82AEF049F649</gtr:id><gtr:impact>I give a plenary talk on the current research in primary Sjogren's syndrome at the conference</gtr:impact><gtr:outcomeId>56d1bf1004fb82.43979271</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Translational research partnership with several pharmaceutical companies to develop/test novel therapeutic targets for primary Sjogren's syndrome</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DD7D5544-F9E0-42F7-BE18-7277EED88B40</gtr:id><gtr:impact>Consultation agreements, collaborative research activities

Facilitate development of novel therapies for primary Sjogren's syndrome</gtr:impact><gtr:outcomeId>eCVTwEgTUaR</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk (ACR 2014)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B5EAF0ED-2B59-4D4C-A94A-B117BA505B1E</gtr:id><gtr:impact>Oral presentation at ACR (SjS/SLE session)</gtr:impact><gtr:outcomeId>56d1c18e6cb942.54842696</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BSR Annual Conference (2015)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9B2CE459-41CC-4F26-B14E-DC47431DCF5A</gtr:id><gtr:impact>I give a talk on the impact of the UK primary Sjogren's syndrome Registry on research into the condition</gtr:impact><gtr:outcomeId>56d1be7ba6c925.64433061</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Internet</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>42F16968-3E04-434A-9CBD-A4F15A1912EC</gtr:id><gtr:impact>we have redesigned our website (www.sjogrensregistry.org) by introducing a &amp;quot;blog&amp;quot;, &amp;quot;running headlines&amp;quot; and &amp;quot;News&amp;quot;, we have markedly improved our internet presence: the number of visits to the site has risen from &amp;lt;10 a month to an average of &amp;gt;1000 visits per month at present, with a total of &amp;gt;11,000 visitors to our website.</gtr:impact><gtr:outcomeId>E124Wx57BQR</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Internet video interview (Berlin 2012)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DA42E0DE-B07C-416A-8C10-9AE8F7401438</gtr:id><gtr:impact>I was interviewed by the company Congress Media which produce Highlights of the European League Against Rheumatism 2012 for people who cannot attend the conference or delegates who cannot attend all the sessions to view the key papers presented at the conference

Increase the profile of the UKPSSR</gtr:impact><gtr:outcomeId>q7ryhrDWemm</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk (Sjogren's Foundation, Boston)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>06162793-F014-4EB7-907E-87FC9A19E6BB</gtr:id><gtr:impact>Presentation of the UK Sjogren's syndrome registry</gtr:impact><gtr:outcomeId>56d1c210b4fd93.89306429</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Paper presentation - BSR (2010)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>33AAA4A6-4E08-4020-A3DF-D1C10488EAFC</gtr:id><gtr:impact>Poster presentations at the British Society for Rheumatology Annual Meeting, Liverpool, 20-23 April, 2010

Improve the profile of the UKPSSR and project update for participants of the project</gtr:impact><gtr:outcomeId>ceV8UyJVi5W</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scientific Advisory Board</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>42AD0D57-BE82-4453-8D15-C09AA8144048</gtr:id><gtr:impact>I have served on scientific advisory board for several pharmaceutical companies planning early phase clinical trials in Sjogren's syndrome and in fatigue.</gtr:impact><gtr:outcomeId>56d1cf40129cf5.88836038</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture (Glasgow 2012)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FA95DBAC-6EBB-421F-95BF-7420EC59AF8B</gtr:id><gtr:impact>Update on the UKPSSR including research outputs at the annual conference of the British Society for Rheumatology (Glasgow, 1-3 May 2012).

Dissemination of the work and output of UKPSSR</gtr:impact><gtr:outcomeId>Rbidi53EtnB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proximity to Discovery</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>DAE95417-786C-43DD-85D3-D7EA46A86E30</gtr:id><gtr:outcomeId>56d1ba734e9b80.43770344</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>280000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Horizon2020</gtr:description><gtr:end>2020-06-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>CE7845DC-B5E5-452C-85BC-0DCE26856173</gtr:id><gtr:outcomeId>58b1c54faa62f7.08349745</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proximity to Discovery</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MC_PC_16080</gtr:fundingRef><gtr:id>23078B48-9149-41A8-B9A3-D58CF48E4BAD</gtr:id><gtr:outcomeId>58b1c4f240ee82.38611241</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>52884</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>The JGW Patterson Foundation</gtr:fundingOrg><gtr:id>E8841302-81C6-4605-A789-7070D3536A04</gtr:id><gtr:outcomeId>58b1c5e8969b01.31638643</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>48750</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Flexibility and sustainability fund</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>519AEDC7-E72B-4F0D-BC86-6BC181767C8B</gtr:id><gtr:outcomeId>L4HBeqLyGzR0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>48610</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Confidence in Concept</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5A7B02D5-9FD8-4C5C-B181-64C6BF11727F</gtr:id><gtr:outcomeId>56d1b64be03941.90855206</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>177122</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Doctoral Training Fellowship</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>20169</gtr:fundingRef><gtr:id>4E31810A-4ED2-4776-ACDE-4D0C085471B6</gtr:id><gtr:outcomeId>iT2QAd2xZ8Q</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Sjogren Syndrome Association project grant</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>British Sjogren's Syndrome Association (BSSA)</gtr:fundingOrg><gtr:id>85AEEF0D-1DAF-44F2-9658-0B971B11B636</gtr:id><gtr:outcomeId>545a1deecfb492.76423263</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>445000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Biological mechanisms of CFS/ME initiative</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J002720/1</gtr:fundingRef><gtr:id>1294BA6F-F8FC-4778-BB7D-EF274AB4E469</gtr:id><gtr:outcomeId>nTgkTJQkYK40</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Sjogren's Syndrome Association Project Grant</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>British Sjogren's Syndrome Association (BSSA)</gtr:fundingOrg><gtr:id>F51D593E-E431-405A-925E-15F2BF9DB900</gtr:id><gtr:outcomeId>C5B3B487B760</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>48000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>JGWP Foundation Trust project grant</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>The JGW Patterson Foundation</gtr:fundingOrg><gtr:id>B3D5AA9C-5338-47DF-837A-DE6976C83662</gtr:id><gtr:outcomeId>545a1d680fb7c6.94003937</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>159609</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK project grant</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>21183</gtr:fundingRef><gtr:id>D0DFD297-3A91-469A-8686-E7AA3065A94C</gtr:id><gtr:outcomeId>56d1b6d26d1d40.23509751</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centre Grant</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>20018</gtr:fundingRef><gtr:id>5BC6CEEC-B189-4BBF-B6CE-B0376F66078D</gtr:id><gtr:outcomeId>56d1b872b976a5.94776533</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>225000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Centre Grant</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>11D0B15C-3302-4152-BAC5-E5B12194E6D8</gtr:id><gtr:outcomeId>R4HxR9yZfU6</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>950000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK clinical trial</gtr:description><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>5B54CCA5-1D7C-4A65-B114-45892D202C24</gtr:id><gtr:outcomeId>DwCVaV4zCk30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Sir Samuel Scott of Yews Trust</gtr:fundingOrg><gtr:id>698A7D3B-D878-4FE7-9112-53FA1472E74D</gtr:id><gtr:outcomeId>euau6v9Kwp4</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>78580</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sir Jules Thorn PhD Scholarship</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Sir Jules Thorn Charitable Trust</gtr:fundingOrg><gtr:id>A6F5A5E4-25A0-4738-9B2B-0B95C232E6F2</gtr:id><gtr:outcomeId>Qk6i2xGi5pE0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK project grant</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>21183</gtr:fundingRef><gtr:id>7965C8A5-4EA1-455B-B1D8-6869647DDA31</gtr:id><gtr:outcomeId>58b1c05c2e9064.68844373</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>593550</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC project grant</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/P002005/1</gtr:fundingRef><gtr:id>1AD8DCA4-B53E-42D5-8917-2B79E08EF0AF</gtr:id><gtr:outcomeId>58b1c26cdfa9b0.73479514</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125701</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARC Project Grant</gtr:description><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>FB3951E9-51D3-4939-9BE8-1A35F8BCCE0E</gtr:id><gtr:outcomeId>623054783AB0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Student Bursary</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Newcastle University</gtr:fundingOrg><gtr:id>E30E30C5-2BC4-4E2B-BD99-856232756B36</gtr:id><gtr:outcomeId>GesbGnqKv3t</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Annoymised clinical data collected for the UK primary Sjogren's syndrome registry</gtr:description><gtr:grantRef>G0800629</gtr:grantRef><gtr:id>0E804334-EB7A-4B6B-83E1-D4F0D01A0297</gtr:id><gtr:impact>The data have been licensed to two pharmaceutical company for their internal use. Data have only been released to the organisations recently so currently uncertain of the impact.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>58bd54df6763f0.99364248</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>UK primary Sjogren's syndrome registry</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited to join the Sjogren's Syndrome Foundation Clinical Trial Consortium (US)</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>A3EC54EB-0611-4563-ADCF-613A5DA15A93</gtr:id><gtr:outcomeId>58bd4e51d0e3b9.68662621</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Led to the appointment of the first UK NIHR Academic clinica fellow in dental radiology</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>D8D85E05-B19E-4A09-8839-542CC27CB9D4</gtr:id><gtr:outcomeId>nM9zysdYz1J</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Leader of the Working Party on Quality Standards of Care for Primary Sjogren's Syndrome</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>559F7210-1E3C-4C87-B7B5-A551BBE9D99F</gtr:id><gtr:outcomeId>f7ZFjWDSwRu</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Committee member of the BSR Management Guideline development group for primary Sjogren's syndrome</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DE09768F-F7A8-4135-B1AA-B47143FCF0DE</gtr:id><gtr:outcomeId>56d1c297d28054.13096941</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited to join the Outcome Measures Online Training Advisory Committee</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D5818456-02DB-490B-8763-7CB911ED402A</gtr:id><gtr:outcomeId>58bd4ed65795e0.62767683</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Steering committee on European League Against Rheumatism best practise guidelines on the management of Sjogren's syndrome</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>6BEC6E85-6F0E-4009-BBBE-25E9F074873D</gtr:id><gtr:outcomeId>HGjgw6kTjfN</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>We have identified a whole blood microRNA signature with good sensitivity and specificity for Sjogren's syndrome patients with lymphoma, we are currently taking advice from our business development unit regarding the suitability for patent application.</gtr:description><gtr:id>1BC5A377-D3F5-4047-AD8D-C84C3536111F</gtr:id><gtr:impact>The potential impact of this biomarker is to improve the current method of detecting lymphoma in patients with primary Sjogren's syndrome</gtr:impact><gtr:outcomeId>cZomjBTAtQY</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>microRNA biomarker for primary Sjogren's syndrome related lymphoma</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Collection of &amp;gt;750 clinically well-characterised patients with associated biobanked samples</gtr:description><gtr:id>B476CF03-136B-4724-93A4-2B482B187F4A</gtr:id><gtr:impact>By 2014, it has led to 15 peer-reviewed publications, leveraged additional research funding and many new research collaborations.</gtr:impact><gtr:outcomeId>545a26cebc1cf7.92992263</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UK primary Sjogren's syndrome registry</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.sjogrensregistry.org</gtr:url><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Serum, DNA, RNA, PBMC</gtr:description><gtr:id>D6705C5A-3169-493A-B60A-EB98E246E054</gtr:id><gtr:impact>Serum samples were sent to Liverpool University for the study of a novel autoantibody in primary Sjogren's syndrome - study ongoing
DNA samples were sent to Oklahoma Medical Research Foundation for a genome-wide association study in primary Sjogren's syndrome. Various other biological samples have subsequently been sent to several other collaborative partners including industrial partners. It has led to 15 peer-reviewed publication, additional grant funding, some of the studies are ongoing</gtr:impact><gtr:outcomeId>ZpH76NisREV</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>UKPSSR biological materials</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Using the biological samples from the UKPSSR, we have now generated data on whole genome expression analyses of whole blood samples from over 300 PSS patients and around 50+ healthy controls.</gtr:description><gtr:id>06DE6533-271C-48FB-AAAA-DD1A27838BD2</gtr:id><gtr:impact>The data were generated in two phases. The data from phase 1 have been published and deposited in the GEO database which is accessible to the public (accession number GSE66795)
The phase 2 data are currently being used for our own study and in another study in collaboration with a research group in France. We are expecting to publish the data in the near future.</gtr:impact><gtr:outcomeId>58bd5334eee801.46437138</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>A large genowide expression datasets</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8590330A-DF1F-4A99-BA24-AF42F67457D4</gtr:id><gtr:title>Impaired functional status in primary Sj&amp;ouml;gren's syndrome.</gtr:title><gtr:parentPublicationTitle>Arthritis care &amp; research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b26f74ea8e57a53372c736edae9acdd"><gtr:id>2b26f74ea8e57a53372c736edae9acdd</gtr:id><gtr:otherNames>Hackett KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2151-464X</gtr:issn><gtr:outcomeId>pm_12951_21_23111856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01E089C9-2F99-4B0D-9D54-52023779915B</gtr:id><gtr:title>Association of genes in the NF-?B pathway with antibody-positive primary Sj&amp;ouml;gren's syndrome.</gtr:title><gtr:parentPublicationTitle>Scandinavian journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2948d4313594ee88110ed29a5b5a57a2"><gtr:id>2948d4313594ee88110ed29a5b5a57a2</gtr:id><gtr:otherNames>Nordmark G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-9475</gtr:issn><gtr:outcomeId>pm_12951_21_23944604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>435D0FA3-E6DE-4295-94DD-ABCED7452D64</gtr:id><gtr:title>Cardiovascular risk factors in women with primary Sj&amp;ouml;gren's syndrome: United Kingdom primary Sj&amp;ouml;gren's syndrome registry results.</gtr:title><gtr:parentPublicationTitle>Arthritis care &amp; research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15b04be05e5903525fb568ff0f557a82"><gtr:id>15b04be05e5903525fb568ff0f557a82</gtr:id><gtr:otherNames>Juarez M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2151-464X</gtr:issn><gtr:outcomeId>pm_540e15de15ddba581</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>378DC55F-F66C-40C4-B6E9-9B039A27AA14</gtr:id><gtr:title>A new MHC-linked susceptibility locus for primary Sj&amp;ouml;gren's syndrome: MICA.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2b3ee248e9135000c6f4b7ea7be3810"><gtr:id>c2b3ee248e9135000c6f4b7ea7be3810</gtr:id><gtr:otherNames>Carapito R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5a10c385173655.88422463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A6ECD2B-BFAB-47EF-A09E-A7793A01E0EC</gtr:id><gtr:title>Do the EULAR Sj&amp;ouml;gren's syndrome outcome measures correlate with health status in primary Sj&amp;ouml;gren's syndrome?</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/942ad273f2defe8d4741f8cf82013b45"><gtr:id>942ad273f2defe8d4741f8cf82013b45</gtr:id><gtr:otherNames>Lendrem D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5458a1973a6f08.97854136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA83FAC3-19AE-46BB-87A0-AC82DA8B5FED</gtr:id><gtr:title>Assessment of blood clot formation and platelet receptor function ex vivo in patients with primary Sjogren's syndrome.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf4bb07eec1914899c848880bf469fbb"><gtr:id>bf4bb07eec1914899c848880bf469fbb</gtr:id><gtr:otherNames>Collins KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pm_12951_21_23793707</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A6550E4-202A-4F36-ADB8-63C9E67379D6</gtr:id><gtr:title>Systemic interferon type I and type II signatures in primary Sj&amp;ouml;gren's syndrome reveal differences in biological disease activity.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0886adc65ce3295f7aa02b5cba8349f"><gtr:id>e0886adc65ce3295f7aa02b5cba8349f</gtr:id><gtr:otherNames>Bodewes ILA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5a96c221ddb8e7.68368593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3155882-648A-42FC-849A-81C6163CAB0C</gtr:id><gtr:title>Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sj&amp;ouml;gren's syndrome.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/124abeb653e0da8651b79d350bd9d868"><gtr:id>124abeb653e0da8651b79d350bd9d868</gtr:id><gtr:otherNames>Lessard CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_12951_21_24097067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DECB88A-5FE4-48DE-B349-E507A2700EE1</gtr:id><gtr:title>Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sj&amp;ouml;gren's Syndrome.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51bc59c8e8990d02f78c2e613ea8de90"><gtr:id>51bc59c8e8990d02f78c2e613ea8de90</gtr:id><gtr:otherNames>Bowman SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>5a10c385735293.71898351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EF57876-A158-4657-889D-82073CC3BB25</gtr:id><gtr:title>Biologic therapies in primary Sj&amp;ouml;gren's syndrome.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51bc59c8e8990d02f78c2e613ea8de90"><gtr:id>51bc59c8e8990d02f78c2e613ea8de90</gtr:id><gtr:otherNames>Bowman SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1389-2010</gtr:issn><gtr:outcomeId>pm_12951_21_22208654</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>640FA1A4-9E98-4805-A095-FC28E09A7A7F</gtr:id><gtr:title>Early diagnosis of primary Sj&amp;ouml;gren's syndrome: EULAR-SS task force clinical recommendations.</gtr:title><gtr:parentPublicationTitle>Expert review of clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2680f1ab9e6ab7fa992d43d6781f779e"><gtr:id>2680f1ab9e6ab7fa992d43d6781f779e</gtr:id><gtr:otherNames>Brito-Zer?n P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1744-666X</gtr:issn><gtr:outcomeId>56d1b41c29d945.37545087</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23474BB5-A668-4408-A77F-6B258528725B</gtr:id><gtr:title>EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b2effbacfa694dbc89297c63cad3ed6"><gtr:id>3b2effbacfa694dbc89297c63cad3ed6</gtr:id><gtr:otherNames>Seror R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_12951_21_21345815</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51B0BAA6-F571-4688-8EDB-1D328EA43192</gtr:id><gtr:title>Germline variation of TNFAIP3 in primary Sj&amp;ouml;gren's syndrome-associated lymphoma.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/430a5b1a8905da6d9714b17ab29d48fc"><gtr:id>430a5b1a8905da6d9714b17ab29d48fc</gtr:id><gtr:otherNames>Nocturne G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>56d1b41b54c194.71422959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A6609E7-9B49-45DF-B058-7816735B94BA</gtr:id><gtr:title>Salivary gland ultrasound abnormalities in primary Sj&amp;ouml;gren's syndrome: consensual US-SG core items definition and reliability.</gtr:title><gtr:parentPublicationTitle>RMD open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ec0241a2b318b38fdd4faf262c1514a"><gtr:id>7ec0241a2b318b38fdd4faf262c1514a</gtr:id><gtr:otherNames>Jousse-Joulin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2056-5933</gtr:issn><gtr:outcomeId>5a10c3848e64a5.55460353</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F24202E9-A6E2-4C3A-930F-2FBA7FE4A5AB</gtr:id><gtr:title>Editorial: Primary Sj&amp;ouml;gren's syndrome research and therapy: has a new dawn arrived?</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6477e5e02c07a568e93385d6ece17cb"><gtr:id>b6477e5e02c07a568e93385d6ece17cb</gtr:id><gtr:otherNames>Ng WF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1389-2010</gtr:issn><gtr:outcomeId>pm_12951_21_22208650</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1CEE23F-5F64-41BC-B2A4-996559F0375D</gtr:id><gtr:title>Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab.</gtr:title><gtr:parentPublicationTitle>Arthritis care &amp; research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6f4f58ecbbbfaf623853fa20499bb6e"><gtr:id>d6f4f58ecbbbfaf623853fa20499bb6e</gtr:id><gtr:otherNames>Helliwell PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2151-464X</gtr:issn><gtr:outcomeId>doi_55f984984b43cacf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31AFC4D4-C593-45E0-BAE1-9B0EA831FAFE</gtr:id><gtr:title>The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96242436a417a2842c132c4123ff35e9"><gtr:id>96242436a417a2842c132c4123ff35e9</gtr:id><gtr:otherNames>Kottyan LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>5458a1970f2348.42239990</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82B5A4E9-21D6-465A-81B4-8B8F4575D5F5</gtr:id><gtr:title>Sj&amp;ouml;gren's syndrome - an update for dental practitioners.</gtr:title><gtr:parentPublicationTitle>British dental journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c73f01c778c6ba0f5bf0ad99ad99008"><gtr:id>6c73f01c778c6ba0f5bf0ad99ad99008</gtr:id><gtr:otherNames>Carr AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0610</gtr:issn><gtr:outcomeId>pm_12951_21_23059671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDD67E22-11F5-4495-B036-EB4B9F4DEF3E</gtr:id><gtr:title>Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sj&amp;ouml;gren's Syndrome.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/430a5b1a8905da6d9714b17ab29d48fc"><gtr:id>430a5b1a8905da6d9714b17ab29d48fc</gtr:id><gtr:otherNames>Nocturne G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>56d1b41be9afe8.03590692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C643A605-F33E-410A-93C9-6F07163EC57B</gtr:id><gtr:title>Primary Sjogren's syndrome: too dry and too tired.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6477e5e02c07a568e93385d6ece17cb"><gtr:id>b6477e5e02c07a568e93385d6ece17cb</gtr:id><gtr:otherNames>Ng WF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>gfTSnQtVveb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87B815AD-B484-4FE8-8AEB-6136CCE2089C</gtr:id><gtr:title>Physical activity but not sedentary activity is reduced in primary Sj&amp;ouml;gren's syndrome.</gtr:title><gtr:parentPublicationTitle>Rheumatology international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6477e5e02c07a568e93385d6ece17cb"><gtr:id>b6477e5e02c07a568e93385d6ece17cb</gtr:id><gtr:otherNames>Ng WF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0172-8172</gtr:issn><gtr:outcomeId>58b18d3b748299.59411319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72F67653-D22D-4A97-956F-9AFFA78ED66A</gtr:id><gtr:title>Klinefelter's syndrome (47,XXY) is in excess among men with Sj&amp;ouml;gren's syndrome.</gtr:title><gtr:parentPublicationTitle>Clinical immunology (Orlando, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25747a8c177e5f0c8aad90b8621c7eff"><gtr:id>25747a8c177e5f0c8aad90b8621c7eff</gtr:id><gtr:otherNames>Harris VM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1521-6616</gtr:issn><gtr:outcomeId>58514f4bde3655.39536010</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61FB82AC-C96E-4A48-8132-09CAAA396DCF</gtr:id><gtr:title>Eligibility for clinical trials in primary Sj&amp;ouml;gren's syndrome: lessons from the UK Primary Sj&amp;ouml;gren's Syndrome Registry.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f1a185d17f84b40caebe0ef1bccef4"><gtr:id>c9f1a185d17f84b40caebe0ef1bccef4</gtr:id><gtr:otherNames>Oni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>5a10c383c09f07.91116918</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92D47474-4377-4344-8A46-20137C8A89CF</gtr:id><gtr:title>Identification of a Sj&amp;ouml;gren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08e3e9b152d63bb3495d9a000cd75f74"><gtr:id>08e3e9b152d63bb3495d9a000cd75f74</gtr:id><gtr:otherNames>Li H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>5a10c384df5579.01221448</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F6195D2-4F71-4D34-9358-D84C68D74EFB</gtr:id><gtr:title>Corrigendum to &amp;quot;Klinefelter's syndrome (47,XXY) is in excess among men with Sj&amp;ouml;gren's syndrome&amp;quot; [Clin. Immunol. 168 (2016) 25-29].</gtr:title><gtr:parentPublicationTitle>Clinical immunology (Orlando, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25747a8c177e5f0c8aad90b8621c7eff"><gtr:id>25747a8c177e5f0c8aad90b8621c7eff</gtr:id><gtr:otherNames>Harris VM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1521-6616</gtr:issn><gtr:outcomeId>5a96c2fdb202a4.26183162</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4385BE7-7F83-4BFB-8681-A12C58D46E1B</gtr:id><gtr:title>Subjective and Objective Measures of Dryness Symptoms in Primary Sj&amp;ouml;gren's Syndrome: Capturing the Discrepancy.</gtr:title><gtr:parentPublicationTitle>Arthritis care &amp; research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7bfd76a86bba97cae01c56b6a938a4a"><gtr:id>b7bfd76a86bba97cae01c56b6a938a4a</gtr:id><gtr:otherNames>Bezzina OM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2151-464X</gtr:issn><gtr:outcomeId>58b18d3bc3a480.17387847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21F003E0-6A1A-47FA-B8B9-0F2F55742589</gtr:id><gtr:title>Health-related utility values of patients with primary Sj&amp;ouml;gren's syndrome and its predictors.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/942ad273f2defe8d4741f8cf82013b45"><gtr:id>942ad273f2defe8d4741f8cf82013b45</gtr:id><gtr:otherNames>Lendrem D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_12951_21_23761688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DD402C2-24F2-4F63-8731-A7DB3F729C01</gtr:id><gtr:title>Potential diagnostic utility of anti-centromere antibody in primary Sj&amp;ouml;gren's syndrome in the UK.</gtr:title><gtr:parentPublicationTitle>Clinical rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a9a64396caf2466a686ff4ac24176bc"><gtr:id>2a9a64396caf2466a686ff4ac24176bc</gtr:id><gtr:otherNames>Collins K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0770-3198</gtr:issn><gtr:outcomeId>pm_12951_21_22648094</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E87322A-6B1D-49BD-B89A-3FA44BDFE708</gtr:id><gtr:title>Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sj&amp;ouml;gren's Syndrome.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f01aee55e92ee99444433dc058e18197"><gtr:id>f01aee55e92ee99444433dc058e18197</gtr:id><gtr:otherNames>Sharma R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>5a10c384b6d232.36526576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0F5E313-3C68-4C69-B3EA-C63269600CBA</gtr:id><gtr:title>X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sj&amp;ouml;gren's Syndrome.</gtr:title><gtr:parentPublicationTitle>Arthritis &amp; rheumatology (Hoboken, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94626b3e92592b72e8b1455183092156"><gtr:id>94626b3e92592b72e8b1455183092156</gtr:id><gtr:otherNames>Liu K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2326-5191</gtr:issn><gtr:outcomeId>56d1b41c8b8cc0.48110963</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B630860-8592-4DFE-9F10-058EC735C488</gtr:id><gtr:title>United Kingdom Primary Sjogren's Syndrome Registry--a united effort to tackle an orphan rheumatic disease.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6477e5e02c07a568e93385d6ece17cb"><gtr:id>b6477e5e02c07a568e93385d6ece17cb</gtr:id><gtr:otherNames>Ng WF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>Fq95y6mZhbJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99725BF5-3705-4AB4-AE75-EE7257D90D1D</gtr:id><gtr:title>Biological therapies in primary Sj&amp;ouml;gren's syndrome.</gtr:title><gtr:parentPublicationTitle>Expert opinion on biological therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6477e5e02c07a568e93385d6ece17cb"><gtr:id>b6477e5e02c07a568e93385d6ece17cb</gtr:id><gtr:otherNames>Ng WF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-2598</gtr:issn><gtr:outcomeId>qtTpRKYiKhY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D0A9768-D8AE-408D-9DE9-62C5F28EAE76</gtr:id><gtr:title>Characterization of systemic disease in primary Sj&amp;ouml;gren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ced598633cb3a8f7141c28643cfb0663"><gtr:id>ced598633cb3a8f7141c28643cfb0663</gtr:id><gtr:otherNames>Ramos-Casals M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>56d1b41b1d8355.50596987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7A9CCC6-D1A1-470C-BF88-99B521146B43</gtr:id><gtr:title>Orthostatic intolerance is common in chronic disease--a clinical cohort study.</gtr:title><gtr:parentPublicationTitle>International journal of cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afa82016345f415704bcfe5850a2f651"><gtr:id>afa82016345f415704bcfe5850a2f651</gtr:id><gtr:otherNames>Frith J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-5273</gtr:issn><gtr:outcomeId>545a7110629809.98868039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F625FB0-1D2D-4394-B87F-AF7A8F38B86F</gtr:id><gtr:title>Eligibility for clinical trials in primary Sj&amp;ouml;gren's syndrome: lessons from the UK Primary Sj&amp;ouml;gren's Syndrome Registry.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f1a185d17f84b40caebe0ef1bccef4"><gtr:id>c9f1a185d17f84b40caebe0ef1bccef4</gtr:id><gtr:otherNames>Oni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>56d1b41bbac135.52437388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BCFC709-C509-442B-A64B-4BD821739E3E</gtr:id><gtr:title>Validation of EULAR primary Sj&amp;ouml;gren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b2effbacfa694dbc89297c63cad3ed6"><gtr:id>3b2effbacfa694dbc89297c63cad3ed6</gtr:id><gtr:otherNames>Seror R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5458a197b1fdd3.86904845</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCAE7138-7498-46F3-A32D-14D311FD9AE1</gtr:id><gtr:title>A Transcriptional Signature of Fatigue Derived from Patients with Primary Sj&amp;ouml;gren's Syndrome.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/693b1e1e986b283a9b0feff1c8de8f12"><gtr:id>693b1e1e986b283a9b0feff1c8de8f12</gtr:id><gtr:otherNames>James K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56d1b41c5c5da1.54096854</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7442D392-7B81-402B-87D3-4ED277C6796B</gtr:id><gtr:title>Outcome measures for primary Sj&amp;ouml;gren's syndrome.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b2effbacfa694dbc89297c63cad3ed6"><gtr:id>3b2effbacfa694dbc89297c63cad3ed6</gtr:id><gtr:otherNames>Seror R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>pm_12951_21_22365784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9A2E70F-F986-4B80-8BC9-BA124DD5A584</gtr:id><gtr:title>Primary Sjogrens syndrome is associated with impaired autonomic response to orthostasis and sympathetic failure.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6477e5e02c07a568e93385d6ece17cb"><gtr:id>b6477e5e02c07a568e93385d6ece17cb</gtr:id><gtr:otherNames>Ng WF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>pm_12951_21_22976617</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A25D4C0-5073-45FA-B6E2-1953AD29E15C</gtr:id><gtr:title>A mixed-methods study identifying key intervention targets to improve participation in daily living activities in primary Sj&amp;ouml;gren's syndrome patients.</gtr:title><gtr:parentPublicationTitle>Arthritis care &amp; research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b26f74ea8e57a53372c736edae9acdd"><gtr:id>2b26f74ea8e57a53372c736edae9acdd</gtr:id><gtr:otherNames>Hackett KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2151-464X</gtr:issn><gtr:outcomeId>5a96c2fd61eee4.79381645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3F75CB9-A9DB-42F8-894F-7AF434EB08C2</gtr:id><gtr:title>Accurate detection of changes in disease activity in primary Sj&amp;ouml;gren's syndrome by the European League Against Rheumatism Sj&amp;ouml;gren's Syndrome Disease Activity Index.</gtr:title><gtr:parentPublicationTitle>Arthritis care &amp; research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b2effbacfa694dbc89297c63cad3ed6"><gtr:id>3b2effbacfa694dbc89297c63cad3ed6</gtr:id><gtr:otherNames>Seror R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>2151-464X</gtr:issn><gtr:outcomeId>pm_12951_21_20391511</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4AA9E03-60B4-4A83-9D23-6D537DC5CDD9</gtr:id><gtr:title>Fatigue in primary Sj&amp;ouml;gren's syndrome is associated with lower levels of proinflammatory cytokines.</gtr:title><gtr:parentPublicationTitle>RMD open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bb89d49892919f3cb1bc3847823c40f"><gtr:id>6bb89d49892919f3cb1bc3847823c40f</gtr:id><gtr:otherNames>Howard Tripp N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2056-5933</gtr:issn><gtr:outcomeId>58514f4b6088b2.42429642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E8DEB39-0622-4959-9D78-AA23FE8FB409</gtr:id><gtr:title>Defining disease activity states and clinically meaningful improvement in primary Sj&amp;ouml;gren's syndrome with EULAR primary Sj&amp;ouml;gren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b2effbacfa694dbc89297c63cad3ed6"><gtr:id>3b2effbacfa694dbc89297c63cad3ed6</gtr:id><gtr:otherNames>Seror R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>56d1b41a700ff1.91001322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25E6766F-F600-4AD3-B04F-25A3B886984E</gtr:id><gtr:title>Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sj&amp;ouml;gren's syndrome: examination of data from the UK Primary Sj&amp;ouml;gren's Syndrome Registry.</gtr:title><gtr:parentPublicationTitle>Swiss medical weekly</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0457094a8524dccad80b85413480cae7"><gtr:id>0457094a8524dccad80b85413480cae7</gtr:id><gtr:otherNames>Dumusc A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0036-7672</gtr:issn><gtr:outcomeId>5a96c2fd2959b6.35382786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20E92DFD-158F-484B-93A2-21D145884AE5</gtr:id><gtr:title>Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43874f3c2c95d6884cbceb8d6ce4445a"><gtr:id>43874f3c2c95d6884cbceb8d6ce4445a</gtr:id><gtr:otherNames>Newton JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>pm_12951_21_22562982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>310F9210-0E60-4B00-8CB3-CC4217017B1B</gtr:id><gtr:title>EULAR Sj&amp;ouml;gren's syndrome disease activity index (ESSDAI): a user guide.</gtr:title><gtr:parentPublicationTitle>RMD open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b2effbacfa694dbc89297c63cad3ed6"><gtr:id>3b2effbacfa694dbc89297c63cad3ed6</gtr:id><gtr:otherNames>Seror R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2056-5933</gtr:issn><gtr:outcomeId>56d1b41b847997.91134928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02DAA2E5-3552-4F84-B8F3-4D2F76F95DAB</gtr:id><gtr:title>Developing a service user informed intervention to improve participation and ability to perform daily activities in primary Sj&amp;ouml;gren's syndrome: a mixed-methods study protocol.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b26f74ea8e57a53372c736edae9acdd"><gtr:id>2b26f74ea8e57a53372c736edae9acdd</gtr:id><gtr:otherNames>Hackett KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5458a0b2a90fe3.03586402</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>369F531C-2896-4F20-B654-391C74B7222D</gtr:id><gtr:title>Effect of rituximab on a salivary gland ultrasound score in primary Sj&amp;ouml;gren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d8bab71644a85b4dbeb53b3f3d0b35e"><gtr:id>6d8bab71644a85b4dbeb53b3f3d0b35e</gtr:id><gtr:otherNames>Fisher BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>5a96c2fd881ed2.51939882</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800629</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>986F1CAE-CC43-4D59-8F85-A91971E4C4BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Other</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>